For decades, HPV (human papillomavirus) has been widely associated with cervical cancer. But new research has uncovered its potential role in dermatological cancers as well.

It’s a reminder that cancer diagnostics are evolving, and having a pathology practice that can keep up is paramount. A recent case study published in The New England Journal of Medicine describes a 34-year-old woman with recurrent cutaneous squamous cell carcinoma (cSCC), an aggressive skin cancer. What made her case remarkable wasn’t just the severity, it was the cause.

After undergoing a bone marrow transplant, the patient’s immune system was restored, and the cancer disappeared. When researchers dug deeper, they discovered something groundbreaking: beta-HPV had integrated into her tumor DNA. The virus was producing proteins that directly fueled the tumor’s growth. This finding marks one of the first clear links between beta-HPV and skin cancer.

“These viruses, often present in healthy individuals, cause characteristic wart-like lesions and can potentially lead to skin cancer in those with Epidermodysplasia verruciformis (EV),” said  L. Brent Talbott, M.D., medical director of dermatopathology, Oculus Pathology.

At Oculus Pathology, we believe discoveries like this reinforce the need for integrated, multi-specialty pathology teams. HPV is not only a concern of gynecologic specialists. When a virus that was once thought to only affect cervical tissue is now tied to aggressive skin cancers, having a pathology team that spans gynecologic pathology, dermatopathology, molecular diagnostics, and virology isn’t just nice to have, it’s essential.

An integrated pathology practice, where specialists share knowledge and work collaboratively, gives clinicians the advantage of comprehensive insight. Silos don’t work when medicine changes this fast. And as viral oncology research continues to uncover new mechanisms of disease, your pathology partner must be ready to detect and interpret them.

At Oculus Pathology, our approach is built for this kind of future, where subspecialty depth and seamless collaboration ensure patients get the most informed care possible.

Want to learn how we can support your practice with integrated, specialty-driven pathology?

Source: Ye, P., et al. (2025). Resolution of Squamous-Cell Carcinoma by Restoring T-Cell Receptor Signaling. The New England Journal of Medicine, 393(5).